15.99
+0.195(+1.23%)
Currency In USD
| Previous Close | 15.79 |
| Open | 15.5 |
| Day High | 16.26 |
| Day Low | 15.43 |
| 52-Week High | 17.75 |
| 52-Week Low | 8.03 |
| Volume | 1.24M |
| Average Volume | 1.81M |
| Market Cap | 1.92B |
| PE | -21.9 |
| EPS | -0.73 |
| Moving Average 50 Days | 14.7 |
| Moving Average 200 Days | 13.82 |
| Change | 0.2 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $733.26 as of August 24, 2025 at a share price of $15.985. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $670.23 as of August 24, 2025 at a share price of $15.985.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 19, 2025 8:00 PM GMT
WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
GlobeNewswire Inc.
Jul 23, 2025 8:00 PM GMT
WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE’s proven efficacy, safety, and tole